RXO, INC. (RXO): what the price requires

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/RXO

Headline

Field	Value
Ticker	RXO
Company	RXO, INC.
Current price	$27.19/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin (mid-cycle)	1.4%
Trailing margin (depressed year)	-1.1%
Must persist for	19.1y
Multiple paid	65x mid-cycle operating income

Solve inputs: computed at a 12.3% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.7 years.

Reconcile: at the x-ray's 9.3% required return this reads ~11.8 years; the models below use their own rates.

How unusual the bet is: elevated

Reference	Value
vs own history	+0.53σ
sustained it ~10 years at this level	14%
implied end-window share	1%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	3.22x	2	expensive
Earnings	—	0	—
Relative	0.53x	2	justifies
Growth	0.91x	3	justifies

Families that justify the price: Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=7)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$6.96	3.91x	yes	Reference only (OCF-based, capex excluded): OCF $0.0B
DCF Exit Multiple	Growth	$0.00	—	no	Negative/zero FCF or EBITDA — equity value floored at $0
Relative Valuation	Relative	$50.86	0.53x	yes	P/S fallback (negative EPS): Sector P/S 1.5x × TTM revenue — excluded from consensus
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$8.92	3.05x	yes	Book value floor: BV/sh $8.92, ROE negative
Two-Stage Excess Return	Asset	$8.03	3.39x	yes	Book value with convergence: BV/sh $8.92, ROE converges to ke
Discounted Future Market Cap	Growth	$29.95	0.91x	yes	Rev $5.7B, growth 19% (input: historical growth; tapered), Terminal P/S: 0.7x / 0.8x / 1.0x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$0.00	—	no	Negative/zero EPS — earnings-based value floored at $0
Margin Trajectory	Growth	$104.42	0.26x	yes	Margin ramp: -2% → 12% over 7yr, rev growth 19% (input: historical growth; tapered)
Earnings Power Value	Earnings	$0.42	64.74x	yes	Normalized EBIT (4y avg op income, one-time charges added back) $0.04B × (1−21%) / WACC 9.0% → EPV (no growth) (excluded from median)
Residual Income	Asset	—	—	no	—
Graham Number	Asset	—	—	no	—
EV/EBITDA Relative	Relative	$1.07	25.41x	yes	EBITDA $0.03B × sector EV/EBITDA 13.0x (excluded from median)
FCF Yield	Earnings	—	—	no	—
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	—	—	no	—
ROIC-Justified P/B	Asset	—	—	no	—
P/Sales Sector	Relative	$50.86	0.53x	yes	Revenue $5.73B × sector P/S 1.5x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	—	—	no	—
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net debt	$446.0m
Net debt / NOPAT (after-tax)	7.13x
Net debt / operating income (pre-tax)	5.63x
Share count CAGR (dilution)	10.1%
Burning cash	no

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 1.4%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• RXO is an asset-light freight broker that matches shippers with independent truckers through its own digital platform, so it owns no trucks and earns a spread that swells and shrinks with the freight cycle.
• The company is at the trough: Q1 2026 produced a GAAP net loss of $36 million and just $6 million of adjusted EBITDA, with brokerage volume down 8% year over year.
• The watch item is the Coyote Logistics integration, running ahead of schedule with at least $50 million of annualized synergies expected, layered on top of any freight-market recovery.

Bull Case

RXO is best understood as a cyclical company at the bottom of its cycle, which is the wrong moment to judge it by trailing earnings. It is an asset-light freight broker: it owns no trucks, signs non-exclusive one-year agreements with independent carriers, and earns the spread between what shippers pay and what carriers charge. The filing describes the differentiator as a "proprietary platform" paired with pricing technology that, together, "can unlock incremental profitable growth". In a normal freight market that spread is healthy and the model throws off cash on minimal capital; the current losses reflect a freight recession, not a broken business.

The early signs of a turn are visible in the mix. Q1 2026 truckload gross profit per load rose 9% sequentially, driven by higher spot exposure and better pricing discipline, and the truckload spot mix climbed to 33%, up 600 basis points year over year. Rising spot mix is what happens when capacity tightens and pricing power returns to brokers, the leading edge of a cycle recovery. The less-than-truckload business is already outgrowing the market and gaining share. Operating leverage in brokerage is steep, so when volume and spread both recover, earnings move fast off a low base.

The Coyote acquisition is the self-help layer on top of the cycle. The integration is running ahead of schedule with at least $50 million of annualized synergies expected, and the LTL volume acceleration the company cited is partly the Coyote network coming together. RXO guided Q2 2026 adjusted EBITDA to $27 million to $37 million, a large step up from Q1's $6 million, with continued sequential improvement in truckload gross profit per load. A scaled broker with proprietary technology and a synergy tailwind, bought near the trough of the freight cycle, is the bull case for owning the eventual recovery.

Bear Case

The variable with the most leverage on RXO is one it cannot control: the freight cycle. Brokerage spreads widen and narrow with the balance of truck capacity and shipping demand, and right now both are working against the company. Q1 2026 brokerage volume fell 8% year over year and the business posted a GAAP net loss of $36 million on just $6 million of adjusted EBITDA. The bull case assumes the cycle turns; the bear case notes that freight recessions have repeatedly lasted longer than the market expected, and a broker at trough margins has no cushion if the recovery slips another year.

The business model also depends on relationships RXO does not lock in. The filing is candid that its asset-light approach "relies on our business relationships with independent motor carriers" through "a non-exclusive, one-year, renewable agreement". When capacity tightens in a recovery, carriers can demand more, compressing the very spread the bull case expects to widen, and they are free to take their trucks elsewhere. The technology is a real differentiator, but brokerage is a competitive, fragmented market where larger and digital-native rivals chase the same loads.

The valuation is the hardest part to defend at a trough. Because trailing earnings are negative, the price is read against mid-cycle normalized earnings, and on that basis it sits at about 62 times, implying operating growth held at its self-funding ceiling for roughly 19 years. The relative-multiple methods read the price as cheap on sales, but the only methods that reach it credit a long recovery-and-synergy path; the asset-value methods land well below the price. Net debt is about $446 million, and the Coyote deal was funded partly with stock, so the share count has grown about 10% a year, diluting existing holders. A levered, diluting, deeply cyclical broker priced for a 19-year compounding runway has to deliver both the freight recovery and the synergies in full, with no value-method floor near the current price if either disappoints.

Valuation

Trailing earnings are negative, so the price has to be read against mid-cycle normalized earnings rather than the trough quarter. On that basis the price is about 62 times normalized operating income, which inverts to operating growth held at its self-funding ceiling for roughly 19 years. That is an extreme implied duration, and it reflects two things at once: a genuinely depressed current margin, about negative 1% trailing against a mid-cycle margin near 1.4%, and a price that is paying for a full recovery plus the Coyote synergies. The reliability of any single-point read here is low, precisely because the denominator is a normalized estimate, not an observed number.

The methods split the way they do for a trough cyclical. The relative-multiple methods read the price as cheap on sales, the way a broker at depressed margins looks against a revenue base of about $5.7 billion, while the asset-value methods land well below the price on a book-value floor near $8.92 per share. The growth methods are the only ones that approach the price, and they do so by crediting the recovery and the margin ramp. In plain terms, the price is not supported by current assets or current earnings; it is supported by the bet that the freight cycle turns and the synergies land.

Solvency is the constraint that makes the timing matter. Net debt of about $446 million sits against mid-cycle earnings at roughly 5.6 times, manageable in a recovery but heavier at the trough, and the share count has grown about 10% a year because the Coyote acquisition was funded partly with equity. That dilution is the cost of building scale, and it works against per-share recovery. What a buyer underwrites at this price is a freight-market recovery arriving on a reasonable timeline plus the full capture of the Coyote synergies, with the downside bounded by the book-value floor rather than by current cash flow.

Catalysts

Q1 2026 was a trough quarter with the first signs of pricing returning. Revenue was $1.4 billion, but the company posted a GAAP net loss of $36 million, adjusted EBITDA of just $6 million, and an adjusted net loss of $16 million. The constructive detail was in the mix: truckload gross profit per load rose 9% sequentially on a higher spot mix and better pricing discipline, and the truckload spot mix climbed to 33%, up 600 basis points year over year, the kind of shift that leads a freight-cycle recovery.

The Coyote integration is the controllable catalyst. It is running ahead of schedule with at least $50 million of annualized synergies expected, against $25 million to $30 million of restructuring and integration expense, and it is helping drive less-than-truckload volume growth that is outpacing the market. For Q2 2026 the company guided adjusted EBITDA to $27 million to $37 million, a sharp sequential step up from Q1, assuming roughly flat year-over-year volume with continued improvement in truckload gross profit per load.

What to watch is the freight cycle itself, since brokerage spread and volume swing on truck capacity and shipping demand, and the pace of synergy capture from Coyote. A confirmed inflection in volume and spread would validate the recovery thesis; a prolonged freight slump that delays the turn is the most direct risk. The Q2 EBITDA print against the guided step-up is the near-term test of whether the recovery is underway.

Peer Cohorts (Per Segment, With Filing Citations)

RXO (single reportable segment) (reported)

• XPO (XPO, Inc.)
• (no filing in the citation store)
• CHRW (C.H. ROBINSON WORLDWIDE, INC.)
• (no filing in the citation store)
• LSTR (LANDSTAR SYSTEM, INC.)
• (no filing in the citation store)
• HUBG (HUB GROUP, INC.)
• (no filing in the citation store)
• GXO (GXO Logistics, Inc.)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

RXO Q1 2026 earnings release, May 2026